Skip to main content
. Author manuscript; available in PMC: 2011 Aug 23.
Published in final edited form as: J Rheumatol. 2005 Feb;32(2):231–238.

Table 1.

Rheumatoid factor (RF) ELISA and anti-CCP antibodies in patients with established inflammatory diseases and with noninflammatory diagnoses.

Female, % Age, yrs,
median (IQR)
RF ELISA
Positive, %
Anti-CCP
ELISA
Positive, %
RF ELISA Positive
and Anti-CCP
ELISA Positive, %
WG, n = 10 70 62 (44.5–77) 0 0 0
SLE, n = 10 90 59 (34.5–74) 40 10 10
AS, n = 12 17 47 (37–50.5) 0 0 0
Inflammatory bowel
disease, n = 10
50 62.5 (52–74.5) 30 20 10
Sarcoidosis, n = 10 30 48.5 (37.5–64) 10 0 0
OA, n = 10 60 60.5 (49–72) 10 0 0
Hyperlipidemia, n = 20 40 56 (47–60) 0 0 0
Seropositive RA, n = 22 57 70 (62.5–74) 100 86 86
Seronegative RA*, n = 20 70 62 (53.5–72) 15 25 10
*

Seronegative RA defined on the basis of RF tested by latex agglutination. WG: Wegener’s granulomatosis, SLE: systemic lupus erythematosus, AS: ankylosing spondylitis, OA: osteoarthritis; RA: rheumatoid arthritis.